RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

By sjmartinez • December 3, 2024

Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JY, Moro-Sibilot D, Puri T, Varughese SC, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032. Epub ahead of print. PMID: 39622410.

Tags: EGFR mutation, erlotinib, Hematology/Oncology, NSCLC, overall survival, Publications, ramucirumab

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A.[...]

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B

Davar D, Eroglu Z, Milhem M, Becerra C, Gutierrez M, Ribas A, Di Pace B, Wang T, Zhang H, Ghosh S, Yanamandra N, Borgovan T,[...]

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study

Gupta M, Schoettler ML, Orozco G, Brazauskas R, Bo-Subait S, Battiwalla M, Buchbinder D, Hamilton BK, Savani BN, Schoemans H, Sorror ML, Ahmed S, Badawy[...]